Information: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Information:
Fel:
ID
27841
Beskrivning
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz
Nyckelord
Versioner (5)
- 30/11/2017 30/11/2017 -
- 30/11/2017 30/11/2017 -
- 07/12/2017 07/12/2017 -
- 10/12/2017 10/12/2017 -
- 04/01/2018 04/01/2018 -
Rättsinnehavare
Prof. Dr. med. Georg Heß
Uppladdad den
30 novembre 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Screening Signature GOAL Trial B-cell Lymphoma NCT02499003
Screening Signature Screening GOAL Trial B-cell Lymphoma NCT02499003
Similar models
Screening Signature Screening GOAL Trial B-cell Lymphoma NCT02499003
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Subject ID
Item
Subject ID
text
confirmation patient information
Item
I have reviewed this eCRF and confirm that, to the best of my knowledge, it accurately reflects the study information obtained for this patient. All entries were made either by me or by a person under my supervision who has signed the Delegation and Signature Log
boolean
Date of signature
Item
Date of signature
date
Name of investigator
Item
Name of investigator
text